OncoCyte (NASDAQ:OCX) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and set a $4.25 price target on shares of OncoCyte in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, OncoCyte presently has an average rating of “Hold” and an average target price of $4.06.

OncoCyte Price Performance

Shares of OCX opened at $3.08 on Friday. The company’s fifty day simple moving average is $3.13 and its 200-day simple moving average is $2.93. OncoCyte has a twelve month low of $2.08 and a twelve month high of $4.34.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.36) earnings per share for the quarter. The firm had revenue of $0.10 million during the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.